EMca: serous, endometrioid, normal (miRNA)

To determine the expression profiles of microRNAs (miRNAs) and to examine specific miRNA expression in endometrial serous adenocarcinoma in comparison with normal endometrial tissue and endometrial endometrioid adenocarcinoma. Twenty-one serous adenocarcinoma tissues, 20 endometrioid adenocarcinoma tissues, and 7 normal endometrial tissues were enrolled. miRNA expression profiles were examined using miRNA microarray. After obtaining informed consent, 21 serous adenocarcinoma tissues, 20 endometrioid adenocarcinoma tissues, and 7 normal endometrial tissue were retrieved from the surgical pathology files at Tohoku University Hospital (Sendai, Japan). The research protocol was approved by the Ethics Committee at Tohoku University Graduate School of Medicine (Sendai, Japan). All specimens were obtained from surgery that was performed between January 2001 and December 2006 at Tohoku University Hospital (Sendai, Japan). We also obtained nonpathologic endometrial tissues as normal controls from hysterectomy specimens performed due to non-endometrial carcinomas. No patient had received preoperative irradiation or chemotherapy. The lesions were classified according to the Histological Typing of Female Genital Tract Tumors by the WHO and staged according to the International Federation of Gynecology and Obstetrics system. Only those patients whose endometrial carcinomas were comprised of pure adenocarcinoma and did not have any other histological components were enrolled. These specimens were processed in 10% formalin, fixed for 24-48 hours, paraffin embedded, and thin-sectioned (3 μm). All of these archival specimens were embedded immediately in OCT compound (Sakura Finetechnical, Tokyo, Japan) and stored at -80℃ for further use. Only sections containing a minimum of 90% carcinoma by examination with hematoxylin-eosin staining were used for total RNA preparation. Total RNA, including miRNA, was extracted using a QIAzol Lysis reagent (Qiagen, Valencia, CA, USA) and a miRNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.本研究旨在明确微小核糖核酸（microRNAs, miRNAs）的表达谱，并对比子宫内膜浆液性腺癌与正常子宫内膜组织、子宫内膜样腺癌中的特异性miRNA表达情况。本研究共纳入21例浆液性腺癌组织、20例子宫内膜样腺癌组织及7例正常子宫内膜组织。本研究通过miRNA微阵列检测miRNA的表达谱。在获取知情同意后，研究人员从日本仙台东北大学医院的外科病理档案中调取了上述21例浆液性腺癌组织、20例子宫内膜样腺癌组织及7例正常子宫内膜组织。本研究方案已通过日本仙台东北大学医学研究生院伦理委员会的审查批准。所有标本均采集自2001年1月至2006年12月期间在日本仙台东北大学医院实施的外科手术标本。本研究同时从因非子宫内膜癌指征接受子宫切除术的患者中获取非病理性子宫内膜组织作为正常对照。所有入组患者均未接受过术前放疗或化疗。所有病变均按照世界卫生组织（World Health Organization, WHO）《女性生殖道肿瘤组织学分类》进行分型，并依据国际妇产科联盟（International Federation of Gynecology and Obstetrics, FIGO）系统进行分期。仅纳入子宫内膜癌为纯腺癌、无其他组织学成分的患者。所有标本经10%福尔马林固定24至48小时后进行石蜡包埋与切片（厚度3μm）。所有存档标本均立即使用OCT包埋剂（日本东京樱花Finetechnical公司）进行包埋，并置于-80℃冰箱保存以备后续实验使用。仅选取经苏木精-伊红染色后肿瘤细胞占比不低于90%的切片用于总RNA提取。按照试剂盒说明书，使用QIAzol裂解试剂（美国加利福尼亚州瓦伦西亚凯杰（Qiagen）公司）与miRNeasy迷你试剂盒（凯杰公司）提取包括miRNA在内的总RNA。